Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > For Notable. From "Science" 9Dec 21

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 15, 2022 1:56pm

162 Views

Post# 34430833

RE:RE:For Notable. From "Science" 9Dec 21

February 14, 2022 - Harnessing the Immune System to Treat Cancers - [Cancer Research]

Combining virotherapy with checkpoint inhibitors

"The field is now looking more closely at combining therapeutics, for example administering immunotherapy and virotherapy in different combinations and orders. Using the strengths of each to help each other."

https://www.technologynetworks.com/cancer-research/articles/harnessing-the-immune-system-to-treat-cancer-358080

<< Previous

Bullboard Posts

Next >>

Top 10 pharmaceutical AI stocks